Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer - PubMed (original) (raw)

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

T Toyoizumi et al. Hum Gene Ther. 1999.

Abstract

A replication-selective herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) has shown efficacy both in vitro and in vivo against human non-small cell lung cancer (NSCLC) cell lines but complete eradication of tumor has not been accomplished with a single viral treatment in our murine xenograft models. Therefore, strategies to enhance the efficacy of this treatment were investigated. We determined the oncolytic activity of HSV-1716 in NCI-H460 cells in combination with each of four chemotherapeutic agents: mitomycin C (MMC), cis-platinum II (cis-DDP), methotrexate (MTX), or doxorubicin (ADR). Isobologram analysis was performed to evaluate the interaction between the viral and chemotherapeutic agents. The oncolytic effect of HSV-1716 in combination with MMC was synergistic in two of five NSCLC cell lines. In the other three cell lines, the combined effect appeared additive. No antagonism was observed. The in vivo effect of this combination was then examined in a murine xenograft model. NCI-H460 flank tumors were directly injected with HSV-1716 (4 x 106 PFU) followed by intravenous MMC administration (0.17 mg/kg) 24 hr later. After 3 weeks, the mean tumor weight in the combined treatment group was significantly less than either individual treatment in an additive manner. The synergistic dose of MMC neither augmented nor inhibited viral replication in vitro and HSV-1716 infection did not upregulate DT-diaphorase, which is the primary enzyme responsible for MMC activation. In summary, the combination of HSV-1716 with common chemotherapeutic agents may augment the effect of HSV-based therapy in the treatment of NSCLC.

PubMed Disclaimer

Cited by

Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y, Nishikawa SG, Fratiloiu AR, Tsutsui M, Kataoka H, Joh T, Johnston RN. Mori Y, et al. Viruses. 2023 Jun 29;15(7):1472. doi: 10.3390/v15071472. Viruses. 2023. PMID: 37515160 Free PMC article.
Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells.
Davola ME, Cormier O, Vito A, El-Sayes N, Collins S, Salem O, Revill S, Ask K, Wan Y, Mossman K. Davola ME, et al. Cancers (Basel). 2023 Feb 17;15(4):1295. doi: 10.3390/cancers15041295. Cancers (Basel). 2023. PMID: 36831636 Free PMC article.
Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Shalhout SZ, et al. Nat Rev Clin Oncol. 2023 Mar;20(3):160-177. doi: 10.1038/s41571-022-00719-w. Epub 2023 Jan 11. Nat Rev Clin Oncol. 2023. PMID: 36631681 Review.
In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells.
Delic M, Boeswald V, Goepfert K, Pabst P, Moehler M. Delic M, et al. Onco Targets Ther. 2022 Oct 27;15:1291-1307. doi: 10.2147/OTT.S350136. eCollection 2022. Onco Targets Ther. 2022. PMID: 36310770 Free PMC article.
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO, Hong J, Yoon AR. Yun CO, et al. Front Immunol. 2022 Aug 25;13:953410. doi: 10.3389/fimmu.2022.953410. eCollection 2022. Front Immunol. 2022. PMID: 36091031 Free PMC article. Review.

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer - PubMed (original) (raw)